Table 2.
Natural products targeting the phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin signaling pathway in triple negative breast cancer
|
Natural product class
|
Natural product name
|
Mechanism of action/inhibition
|
Ref.
|
| Flavonoids | Prenylated xanthones | Decrease the levels of PI3K, AKT, and mTOR in both total protein and phosphorylated forms | [75] |
| Ononin | Reverse EMT through down-regulation of EMT markers and matrix metalloproteinases, attenuate EGFR phosphorylation and inhibit the PI3K/Akt/mTOR pathway | [76] | |
| Myricetin | Inhibit the PI3K/Akt/mTOR pathway to enhance the anti-cancer efficacy of Myricetin | [77] | |
| Quercetin | Decrease cell viability, colony formation, angiogenesis, and increase apoptosis. Inhibit the activation of IGF1R and its downstream kinases AKT and ERK1/2. Suppress E-mediated proliferation and migration of TNBC cells by blocking β2-AR/ERK1/2 pathway | [78,80,81] | |
| Terpenoids | PAB | Induces apoptosis through mitochondrial apoptosis and the PI3K/Akt/mTOR pathway | [87] |
| Ezhu | Inhibit the proliferation, invasion, migration, and EMT of MDA-MB-231 cells through the PI3K/Akt/mTOR signaling pathway | [89] | |
| Tan IIA | Enhance the antitumor efficacy of doxorubicin by interfering with the PI3K/AKT/mTOR signaling pathway and inhibiting topoisomerase II | [79] | |
| Alkaloids | RTEs | Enhance the sensitivity of resistant TNBC cells to Taxol through their inhibitory effect on PI3K/Akt/mTOR-mediated autophagy. Suppress MDA-MB-468/Taxol cells autophagy and reduce tumor growth | [91] |
| BJE | Inhibit the proliferation, induce apoptosis, and promote the phosphorylation of mTOR, PI3K, and Akt in MDA-MB-231 TNBC cells | [68] | |
| PIP | Suppress the pro-survival AKT pathway and induce caspase-dependent apoptosis via the mitochondrial pathway. Impair the in vitro migratory capacity of TNBC cells and reduce MMP-2 and MMP-9 mRNA expression. The combination of doxorubicin and PIP can increase necrosis while downregulating PTEN, inhibiting PI3K levels, and the immunoreactivity of p-Akt, mTOR, and ALDH-1 | [98,99] | |
| BBM | Impede TNBC development through regulation of the PI3K/Akt/MDM2/p53 and PI3K/Akt/mTOR signaling pathways | [100] | |
| HHT | Downregulate p-AKT, p-mTOR, and Bcl-2 expression, while upregulating TP53, Bax, cleaved caspase-3, and caspase-9 expression, and inhibiting the PI3K/AKT/mTOR pathway | [101] |
PAB: Pseudolaric acid B; Tan IIA: Tanshinone IIA; RTEs: Radix tetrastigma extracts; BJE: Brucea javanica seed; PIP: Piperine; BBM: Berbamine; HHT: Homoharringtonine; PI3K: Phosphoinositide 3-kinase; Akt: Protein kinase B; mTOR: Mechanistic target of rapamycin; EMT: Epithelial-mesenchymal transition; EGFR: Epidermal growth factor receptor; IGF1R: Insulin-like growth factor-1 receptor; ERK: Extracellular signal-regulated kinase; TNBC: Triple negative breast cancer; MMP: Matrix metalloproteinase; PTEN: Phosphatase and tensin homolog; PIP: Piperine; MDM2: Murine double minute 2; ALDH-1: Aldehyde dehydrogenase-1.